GSK Consumer (SKB IN) Healthy enough to drive growth

INDIA | FMCG | Company Update

We believe recent correction (12%) provides an attractive risk-reward as Indian business remains on strong footing 1) driven by change in management, whose priority is profitable volume growth 2) focus on high margin science based products and 3) driving penetration by pushing Low unit packs in rural areas. In our view, correction in GSK consumer stock price is unwarranted and even if deal goes through, it is likely to happen at premium valuations (vs current market cap) as 1) well funded competitors making a beeline for iconic brand and 2) scarcity premium for health related brands in India. We reiterate our high conviction BUY with TP of 7160 (35x FY20 EPS) with 23% upside.

New management team to focus on volume growth – GSK consumer saw compounded annual sales decline of 4% over FY15-17 due to management excessive focus on pricing over volume's (6%+ price Cagr over past 5 years resulted in gross margin improving to 66% in FY17 from 62% in CY11) which led to price-value equation going for a toss; moreover this collided alongwith a) category and economic slowdown and b) emergence of value players (Power Vita). We can draw parallel between the new management team (**refer table 4**) with Suresh Narayanan, MD of Nestle India, where growth has made strong comeback driven by focus on volume in core categories via innovation and leveraging existing distribution network and entry into new categories. We believe new management strategy –1) product simplification 2) innovation and 3) improving execution capability on distribution front to bear fruits in medium term.

Science based products to drive next leg of growth – We believe GSK consumer's management also has acknowledged following challenges in driving growth of core categories -

- Increased availability of milk in South and East India, key markets (c80%+ of sales).
- Children preferring to have cereals (cornflakes, Chocó's etc) with milk rather than malted foods.
- Better quality of milk reducing need of taste enhancer.

Management plans to revive growth by launching 1) more science based products and 2) gradual increase in tie-up with healthcare professionals (**refer table 1 and 3**)

- Growth Plus targeting children in age group of 3-9 years (competing with PediaSure from Abbott).
- Cardia plus helps to reduce cholesterol, blood sugar and manage weight.
- Protein Plus targeting working adults, who may be protein deficient due to hectic lifestyle (competing with Protinex from Danone).

Driving penetration via LUP at the bottom of the pyramid – Our channel checks suggest that company is focussing on LUP's (Rs 5,10) primarily in rural areas to drive penetration, but its availability has been limited in urban areas due to management's fear that it may cannibalize sales of big packs. Our ground checks suggest that Horlicks powder when put in idle glass/plastic bottle faces risk of attracting moisture thereby reducing consumption and consumer are finding single serving sachets to be more convenient and easy to use. We expect management to focus on LUP's gets compensated by higher volumes, thereby recruiting new users and expanding the base.

Who are likely to be contenders for the brand/company? - Within listed space, Nestle is best suited to acquire GSK consumer given its 1) deep knowledge of malted food category worldwide through Milo and 2) focus on health and wellness categories; however MNC companies like HUL and Nestle may face issues in structuring the deals as parent of these companies may not be willing to dilute stake in respective Indian arm's. We believe it will be relatively easy for ITC to structure the deal since it does not have promoter dilution related





2 April 2018

Buy (Maintain)

CMP RS 5832 TARGET RS 7160 (+23%)

COMPANY DATA

O/S SHARES (MN) :	42
MARKET CAP (RSBN) :	245
MARKET CAP (USDBN) :	4
52 - WK HI/LO (RS) :	6888 / 4856
LIQUIDITY 3M (USDMN) :	1.8
PAR VALUE (RS) :	10

SHARE HOLDING PATTERN, %

	Dec 17	Sep 17	Jun 17
PROMOTERS :	72.5	72.5	72.5
FII / NRI :	4.1	4.0	4.2
FI / MF :	8.7	8.9	8.6
NON PRO :	2.7	2.7	2.7
PUBLIC & OTHERS :	12.0	12.0	12.0

PRICE PERFORMANCE, %

	1MTH	3MTH	1YR
ABS	-14.1	-10.0	13.0
REL TO BSE	-11.4	-7.6	0.4

PRICE VS. SENSEX



Source: Phillip Capital India Research

KEY FINANCIALS

Rs mn	FY17	FY18E	FY19E	FY20E
Net Sales	37,739	41,531	45,902	50,663
EBIDTA	8,335	8,792	10,020	11,135
Net Profit	6,567	6,854	7,753	8,602
EPS, Rs	156	163	184	205
PER, x	37.4	35.8	31.6	28.5
EV/EBIDTA, x	25.7	23.7	20.7	17.0
ROE, %	21.0	19.9	20.4	20.5

Source: PhillipCapital India Research Est.

Vishal Gutka (+ 9122 6246 4118) vgutka@phillipcapital.in

Naveen Kulkarni & Preeyam Tolia

Issues and increasing focus on dairy segment (recently launched Aashirvaad milk in Bihar and has been present in ghee segment for a while). In unlisted space, we believe all MNC's – Danone, Abbott, and Kraft – Heinz (Complan) and Mondelez (Bourvita) are equally competent in acquiring GSK consumer business. We do not foresee any major challenges in current distribution structure for distributing OTC products since acquirer will keep receiving distribution fees post sale of business.

What can be done with the Horlicks brand? - We believe Horlicks enjoys enormous brand equity in health related space and can be easily expanded into adjacent categories like protein bars, museli, launching Horlicks in ready to drink format (Nestle has recently launched RTD Milo in India) and further expanding biscuit range. Large FMCG companies (ITC, Nestle, HUL etc) can leverage their distribution network since current distribution strength of GSK consumer is restricted to 3-3.5 m outlets.

Table 1: Science based product comparison

Company	Brands	Grammage	MRP	Rs /Kg	Discount to Competition
	Children (Plus 2-9 years)			., 0	
GSK Consumer	Horlicks Growth Plus (Jar)	400g	520	1,300	-4%
Abbott	Pediasure (Jar)	400g	540	1,350	
	Performance				
GSK Consumer	Horlicks Protein Plus (Jar)	400g	495	1,238	-15%
Danone	Protinex (Jar)	400g	585	1,463	
	Medical				
GSK Consumer	Cardia Plus (Jar)	400g	680	1,700	
Courses Die Dooloof	. C				

Source: Big Basket, Company

Company	Brands	Grammage	MRP	Rs/Kg
	Base Drink			
GSK Consumer	Horlicks Classic Malt	500g	215	430
GSK Consumer	Boost	500g	210	420
Mondelez	Bournvita Pro-Health Chocolate drink	500g	199	398
Patanjali	Power Vita	500g	180	360
Sri Sri Products	Ojas Vita	500g	250	500
	Infant			
Nestle	Lactogen - Stage 1	400g	302	755
Abbott	Similac - Stage 1	400g	525	1,313
	Children			
GSK Consumer	Junior Horlicks - Stage 1 (2-3 years)	500g	256	512
Kraft- Heinz	Complan	500g	220	440
Mondelez	Bournvita Lil' Champs	500g	262	524
GSK Consumer	Horlicks Growth Plus (3-9 years) (Jar)	400g	520	1,300
Abbott	PediaSure (Jar)	400g	540	1,350
	Women			
GSK Consumer	Women's Horlicks - Chocolate (Jar)	400g	270	675
	Mother (Pregnancy/ breast-feeding)			
GSK Consumer	Mother Horlicks	450g	456	1,013
Nestle	Nestle Mom & Me	400g	440	1,100
Danone	Mama Protinex	400g	560	1,400
	Performance			
Abbott	Ensure (Jar)	400g	485	1,213
Danone	Protinex (Jar)	400g	585	1,463
GSK Consumer	Horlicks Protein Plus (Jar)	400g	495	1,238
	Specialized			
GSK Consumer	Cardia Plus (Jar)	400g	680	1,700

Products	Grammage	MRP	Rs/Kg
Boost	500g	210	420
Horlicks Classic Malt	500g	215	430
Junior Horlicks - Stage 1 (2-3 years)	500g	256	512
Mother Horlicks	450g	456	1,013
Horlicks Protein Plus (Jar)	400g	495	1,238
Horlicks Growth Plus (3-9 years) Jar	400g	520	1,300
Horlicks Cardia Plus (Jar)	400g	680	1,700

Source: Big Basket, Company



Management Profile

Table 4 - Management profile Mr. Navneet Saluja Role Tenure Company Experience Jan-18 - Present GSK Consumer India Managing Director Jan-13 GSK Midle East & Africa VP & General Manger Nov-08 GSK India Head of sales Reliance Retail Setup North India Operations 1.5-2 years Reliance Infocomm Kellogg's Head of sales in Marketing and Director 1.5 years 11 years Gillette Sales & Marketing 4 years Cadbury Sales & Marketing **Education Qualification** 1987 JBIMS - Mumbai Post Graduation

Mr. Vikram Bahl

	Year	Company	Designation
Experience	May 2017 - Present	GSK Consumer Healthcare India	Executive VP Marketing
	Feb 2014 - April 2017	Kellogg Company	Global Innovation Lead - Savory and Natural Snacks
	Jan 2013 - Feb 2014	Kellogg Company	Brand Lead - Cheez It
	Jul 2008 - Dec 2012	Kellogg Company	MD. India & South Asia
	Jan 2006 - Jun 2008	P&G	Regional Marketing Manager, ASEAN
	Apr 2002 - Dec 2005	Gillette	Marketing Manager
	Jul 1999 - Mar 2002	P&G	Regional Brand Manager - AMEE
	Aug 1996 - Jun 1999	P&G	Brand Manager
	Jun 1993 - Jul 1996	Wipro Consumer Care and Lighting	Area Sales Manager
Education Qualification	1991 -1993	IIM - Bangalore	PGDM, Marketing & Finance
	1988 - 1991	St. Stephen's College	

Source: LinkedIn, Company



Financials

Income Statement

Y/E Mar, Rs mn	FY17	FY18E	FY19E	FY20E
Net sales	37,739	41,531	45,902	50,663
Growth, %	-4	10	11	10
Total income	39,865	43,762	48,178	53,053
Raw material expenses	-12,969	-14,604	-15,918	-17,589
Employee expenses	-4,580	-5,267	-5,636	-6,059
Other Operating expenses	-13,980	-15,099	-16,604	-18,270
EBITDA (Core)	8,335	8,792	10,020	11,135
Growth, %	(0.6)	5.5	14.0	11.1
Margin, %	22.1	21.2	21.8	22.0
Depreciation	-642	-666	-802	-939
EBIT	7,693	8,127	9,218	10,196
Growth, %	(1.5)	5.6	13.4	10.6
Margin, %	20.4	19.6	20.1	20.1
Interest paid	-28	-16	-16	-16
Other Non-Operating Income	2,439	2,500	2,800	3,136
Pre-tax profit	10,104	10,610	12,002	13,316
Tax provided	-3,537	-3,756	-4,249	-4,714
Profit after tax	6,567	6,854	7,753	8,602
Net Profit	6,567	6,854	7,753	8,602
Growth, %	(4.5)	4.4	13.1	10.9
Net Profit (adjusted)	6,567	6,854	7,753	8,602
Unadj. shares (m)	42	42	42	42
Wtd avg shares (m)	42	42	42	42

GSK CONSUMER COMPANY UPDATE

Cash Flow

	FY17	FY18E	FY19E	FY20E
Pre-tax profit	10,104	10,610	12,002	13,316
Depreciation	642	666	802	939
Chg in working capital	1,186	3,340	-1,991	14,262
Total tax paid	-4,087	-3,756	-4,249	-4,714
Other operating activities	219	-700	-700	-700
Cash flow from operating activities	8,063	10,160	5,865	23,103
Capital expenditure	-766	-789	-1,575	-1,575
Cash flow from investing activities	-766	-789	-1,575	-1,575
Free cash flow	7,297	9,370	4,290	21,528
Equity raised/(repaid)	0	700	700	700
Dividend (incl. tax)	-3,543	-3,701	-4,187	-4,645
Cash flow from financing activities	-3,543	-3,001	-3,487	-3,945
Net chg in cash	3,754	6,369	803	17,583


Valuation Ratios

	FY17	FY18E	FY19E	FY20E
Per Share data				
EPS (INR)	156	163	184	205
Growth, %	(4.5)	4.4	13.1	10.9
Book NAV/share (INR)	742	817	902	996
FDEPS (INR)	156	163	184	205
CEPS (INR)	171	179	203	227
CFPS (INR)	129	199	90	491
DPS (INR)	70.0	73.3	83.0	92.0
Return ratios				
Return on assets (%)	13.9	13.2	13.7	12.7
Return on equity (%)	21.0	19.9	20.4	20.5
Return on capital employed (%)	22.2	20.9	21.5	21.6
Turnover ratios				
Asset turnover (x)	(31.1)	(12.4)	(12.8)	(5.6)
Sales/Total assets (x)	0.8	0.8	0.8	0.7
Sales/Net FA (x)	7.0	7.5	7.7	7.6
Working capital/Sales (x)	(0.2)	(0.3)	(0.2)	(0.5)
Fixed capital/Sales (x)	0.7	0.6	0.6	-
Working capital days	(69.6)	(92.6)	(67.9)	(164.3)
Liquidity ratios				
Current ratio (x)	2.3	2.3	2.4	1.9
Quick ratio (x)	2.0	2.2	2.1	1.8
Interest cover (x)	276.7	507.9	576.1	637.3
Dividend cover (x)	2.2			
Net debt/Equity (%)	(98.9)	(108.3)	(100.3)	(132.8)
Valuation				
PER (x)	37.4	35.8	31.6	28.5
Price/Book (x)	7.9	7.1	6.5	5.9
Yield (%)	1.2	1.3		
EV/Net sales (x)	5.7	5.0	4.5	3.7
EV/EBITDA (x)	25.7	23.7	20.7	17.0
EV/EBIT (x)	27.9	25.6	22.5	18.6

Balance Sheet				
Y/E Mar, Rs mn	FY17	FY18E	FY19E	FY20E
Cash & bank	30,874	37,243	38,046	55,633
Debtors	3,210	2,934	3,857	3,639
Inventory	4,611	3,390	5,332	4,306
Loans & advances	2,182	1,661	1,836	2,027
Other current assets	1,178	1,666	1,478	1,992
Total current assets	42,056	46,895	50,548	67,597
Gross fixed assets	6,316	7,316	8,816	10,316
Less: Depreciation	-1,442	-2,108	-2,910	-3,849
Add: Capital WIP	577	366	441	516
Net fixed assets	5,451	5,574	6,347	6,983
Total assets	49,602	54,564	58,990	76,675
Current liabilities	18,375	20,185	21,044	34,772
Total current liabilities	18,375	20,185	21,044	34,772
Non-current liabilities	4	4	4	0
Total liabilities	18,379	20,189	21,048	34,772
Paid-up capital	421	421	421	421
Reserves & surplus	30,802	33,955	37,521	41,482
Shareholders' equity	31,223	34,375	37,942	41,903
Total equity & liabilities	49,602	54,564	58,990	76,675

Source: Company, PhillipCapital India Research Estimates





Stock Price, Price Target and Rating History

Rating Methodology

We rate stock on absolute return basis. Our target price for the stocks has an investment horizon of one year.

Rating	Criteria	Definition
BUY	>= +15%	Target price is equal to or more than 15% of current market price
NEUTRAL	-15% > to < +15%	Target price is less than +15% but more than -15%
SELL	<= -15%	Target price is less than or equal to -15%.



(91 22) 2483 1919

(91 22) 6246 4101 (91 22) 6667 9735

Maı	12	n			пт
IVICI	ICI	w	-	161	

Vineet Bhatnagar (Managing Director) Kinshuk Bharti Tiwari (Head - Institutional Equity) Jignesh Shah (Head – Equity Derivatives)

Research

Automobiles	
Dhawal Doshi	(9122) 6246 4128
Nitesh Sharma, CFA	(9122) 6246 4126
Agro Chemicals	
Varun Vijayan	(9122) 6246 4117
Banking, NBFCs	
Manish Agarwalla	(9122) 6246 4125
Pradeep Agrawal	(9122) 6246 4113
Paresh Jain	(9122) 6246 4114
Consumer & Retail	
Naveen Kulkarni, CFA, FRM	(9122) 6246 4122
Preeyam Tolia	(9122) 6246 4129
Vishal Gutka	(9122) 6246 4118
Akshay Mokashe	(9122) 6246 4130
Cement	
Vaibhav Agarwal	(9122) 6246 4124
Economics	
Anjali Verma	(9122) 6246 4115
Sales & Distribution	
Ashvin Patil	(9122) 6246 4105
Kishor Binwal	(9122) 6246 4106
Bhavin Shah	(9122) 6246 4102
Ashka Mehta Gulati	(9122) 6246 4108
Archan Vyas	(9122) 6246 4107

Engineering, Capital Goods	
Jonas Bhutta	(9122) 6246 4119
Vikram Rawat	(9122) 6246 4120
IT Services	
Vibhor Singhal	(9122) 6246 4109
Shyamal Dhruve	(9122) 6246 4110
Infrastructure	
Vibhor Singhal	(9122) 6246 4109
Logistics, Transportation & Mi	dcap
Vikram Suryavanshi	(9122) 6246 4111
Media	
Naveen Kulkarni, CFA, FRM	(9122) 6246 4122
Vishal Gutka	(9122) 6246 4118
Metals	
Dhawal Doshi	(9122) 6246 4128
Vipul Agrawal	(9122) 6246 4127
Mid-Caps	
Deepak Agarwal	(9122) 6246 4112
Asia Sales	
Dhawal Shah	8522 277 6747
Sales Trader	
Dilesh Doshi	(9122) 6667 9747
Suniil Pandit	(9122) 6667 9745

Pharma & Specialty Chem	
Surya Patra	(9122) 6246 412
Mehul Sheth	(9122) 6246 412
Raag Haria	(9122) 6667 994
Strategy	
Naveen Kulkarni, CFA, FRM	(9122) 6246 412
Neeraj Chadawar	(9122) 6246 411
Telecom	
Naveen Kulkarni, CFA, FRM	(9122) 6246 412
Technicals	
Subodh Gupta, CMT	(9122) 6246 413
Production Manager	
Ganesh Deorukhkar	(9122) 6667 996
Editor	
Roshan Sony	98199 7272
Sr. Manager – Equities Supp	ort
Rosie Ferns	(9122) 6667 997
Corporate Communica	tions
Zarine Damania	(9122) 6667 997

Contact Information (Regional Member Companies)

SINGAPORE: Phillip Securities Pte Ltd MALAYSIA: Phillip Capital Management Sdn Bhd 250 North Bridge Road, #06-00 RafflesCityTower, B-3-6 Block B Level 3, Megan Avenue II, Singapore 179101 No. 12, Jalan Yap Kwan Seng, 50450 Kuala Lumpur Tel : (65) 6533 6001 Fax: (65) 6535 3834 Tel (60) 3 2162 8841 Fax (60) 3 2166 5099 www.phillip.com.sg www.poems.com.my JAPAN: Phillip Securities Japan, Ltd INDONESIA: PT Phillip Securities Indonesia 4-2 Nihonbashi Kabutocho, Chuo-ku ANZTower Level 23B, Jl Jend Sudirman Kav 33A, Tokyo 103-0026 Jakarta 10220, Indonesia Tel: (81) 3 3666 2101 Fax: (81) 3 3664 0141 Tel (62) 21 5790 0800 Fax: (62) 21 5790 0809 www.phillip.co.jp www.phillip.co.id THAILAND: Phillip Securities (Thailand) Public Co. Ltd. FRANCE: King & Shaxson Capital Ltd. 15th Floor, VorawatBuilding, 849 Silom Road, 3rd Floor, 35 Rue de la Bienfaisance Silom, Bangrak, Bangkok 10500 Thailand 75008 Paris France Tel (66) 2 2268 0999 Fax: (66) 2 2268 0921 Tel (33) 1 4563 3100 Fax : (33) 1 4563 6017 www.phillip.co.th UNITED STATES: Phillip Futures Inc.

www.kingandshaxson.com AUSTRALIA: PhillipCapital Australia Level 10, 330 Collins Street The Chicago Board of TradeBuilding Melbourne, VIC 3000, Australia Tel: (61) 3 8633 9800 Fax: (61) 3 8633 9899 Tel (1) 312 356 9000 Fax: (1) 312 356 9005 www.phillipcapital.com.au

INDIA

PhillipCapital (India) Private Limited

No. 1, 18th Floor, Urmi Estate, 95 Ganpatrao Kadam Marg, Lower Parel West, Mumbai 400013 Tel: (9122) 2483 1919 Fax: (9122) 6667 9955 www.phillipcapital.in

HONG KONG: Phillip Securities (HK) Ltd 11/F United Centre 95 Queensway Hong Kong Tel (852) 2277 6600 Fax: (852) 2868 5307 www.phillip.com.hk

(9122) 6667 9945

Execution

Mayur Shah

CHINA: Phillip Financial Advisory (Shanghai) Co. Ltd. No 550 Yan An East Road, OceanTower Unit 2318 Shanghai 200 001 Tel (86) 21 5169 9200 Fax: (86) 21 6351 2940 www.phillip.com.cn UNITED KINGDOM: King & Shaxson Ltd. 6th Floor, Candlewick House, 120 Cannon Street London, EC4N 6AS Tel (44) 20 7929 5300 Fax: (44) 20 7283 6835 www.kingandshaxson.com SRI LANKA: Asha Phillip Securities Limited Level 4, Millennium House, 46/58 Navam Mawatha, Colombo 2, Sri Lanka Tel: (94) 11 2429 100 Fax: (94) 11 2429 199

www.ashaphillip.net/home.htm

141 W Jackson Blvd Ste 3050

Chicago, IL 60604 USA



Disclosures and Disclaimers

PhillipCapital (India) Pvt. Ltd. has three independent equity research groups: Institutional Equities, Institutional Equity Derivatives, and Private Client Group. This report has been prepared by Institutional Equities Group. The views and opinions expressed in this document may, may not match, or may be contrary at times with the views, estimates, rating, and target price of the other equity research groups of PhillipCapital (India) Pvt. Ltd.

This report is issued by PhillipCapital (India) Pvt. Ltd., which is regulated by the SEBI. PhillipCapital (India) Pvt. Ltd. is a subsidiary of Phillip (Mauritius) Pvt. Ltd. References to "PCIPL" in this report shall mean PhillipCapital (India) Pvt. Ltd unless otherwise stated. This report is prepared and distributed by PCIPL for information purposes only, and neither the information contained herein, nor any opinion expressed should be construed or deemed to be construed as solicitation or as offering advice for the purposes of the purchase or sale of any security, investment, or derivatives. The information and opinions contained in the report were considered by PCIPL to be valid when published. The report also contains information provided to PCIPL by third parties. The source of such information will usually be disclosed in the report. Whilst PCIPL has taken all reasonable steps to ensure that this information is correct, PCIPL does not offer any warranty as to the accuracy or completeness of such information. Any person placing reliance on the report to undertake trading does so entirely at his or her own risk and PCIPL does not accept any liability as a result. Securities and Derivatives markets may be subject to rapid and unexpected price movements and past performance is not necessarily an indication of future performance.

This report does not regard the specific investment objectives, financial situation, and the particular needs of any specific person who may receive this report. Investors must undertake independent analysis with their own legal, tax, and financial advisors and reach their own conclusions regarding the appropriateness of investing in any securities or investment strategies discussed or recommended in this report and should understand that statements regarding future prospects may not be realised. Under no circumstances can it be used or considered as an offer to sell or as a solicitation of any offer to buy or sell the securities mentioned within it. The information contained in the research reports may have been taken from trade and statistical services and other sources, which PCIL believe is reliable. PhillipCapital (India) Pvt. Ltd. or any of its group/associate/affiliate companies do not guarantee that such information is accurate or complete and it should not be relied upon as such. Any opinions expressed reflect judgments at this date and are subject to change without notice.

Important: These disclosures and disclaimers must be read in conjunction with the research report of which it forms part. Receipt and use of the research report is subject to all aspects of these disclosures and disclaimers. Additional information about the issuers and securities discussed in this research report is available on request.

Certifications: The research analyst(s) who prepared this research report hereby certifies that the views expressed in this research report accurately reflect the research analyst's personal views about all of the subject issuers and/or securities, that the analyst(s) have no known conflict of interest and no part of the research analyst's compensation was, is, or will be, directly or indirectly, related to the specific views or recommendations contained in this research report.

Additional Disclosures of Interest:

Unless specifically mentioned in Point No. 9 below:

- 1. The Research Analyst(s), PCIL, or its associates or relatives of the Research Analyst does not have any financial interest in the company(ies) covered in this report.
- 2. The Research Analyst, PCIL or its associates or relatives of the Research Analyst affiliates collectively do not hold more than 1% of the securities of the company (ies)covered in this report as of the end of the month immediately preceding the distribution of the research report.
- 3. The Research Analyst, his/her associate, his/her relative, and PCIL, do not have any other material conflict of interest at the time of publication of this research report.
- 4. The Research Analyst, PCIL, and its associates have not received compensation for investment banking or merchant banking or brokerage services or for any other products or services from the company(ies) covered in this report, in the past twelve months.
- 5. The Research Analyst, PCIL or its associates have not managed or co-managed in the previous twelve months, a private or public offering of securities for the company (ies) covered in this report.
- 6. PCIL or its associates have not received compensation or other benefits from the company(ies) covered in this report or from any third party, in connection with the research report.
- 7. The Research Analyst has not served as an Officer, Director, or employee of the company (ies) covered in the Research report.
- 8. The Research Analyst and PCIL has not been engaged in market making activity for the company(ies) covered in the Research report.
- 9. Details of PCIL, Research Analyst and its associates pertaining to the companies covered in the Research report:

Sr. no.	Particulars	Yes/No
1	Whether compensation has been received from the company(ies) covered in the Research report in the past 12 months for	No
	investment banking transaction by PCIL	
2	Whether Research Analyst, PCIL or its associates or relatives of the Research Analyst affiliates collectively hold more than 1% of	No
	the company(ies) covered in the Research report	
3	Whether compensation has been received by PCIL or its associates from the company(ies) covered in the Research report	No
4	PCIL or its affiliates have managed or co-managed in the previous twelve months a private or public offering of securities for the	No
	company(ies) covered in the Research report	
5	Research Analyst, his associate, PCIL or its associates have received compensation for investment banking or merchant banking or	No
	brokerage services or for any other products or services from the company(ies) covered in the Research report, in the last twelve	
	months	

Independence: PhillipCapital (India) Pvt. Ltd. has not had an investment banking relationship with, and has not received any compensation for investment banking services from, the subject issuers in the past twelve (12) months, and PhillipCapital (India) Pvt. Ltd does not anticipate receiving or intend to seek compensation for investment banking services from the subject issuers in the next three (3) months. PhillipCapital (India) Pvt. Ltd is not a market maker in the securities mentioned in this research report, although it, or its affiliates/employees, may have positions in, purchase or sell, or be materially interested in any of the securities covered in the report.

Suitability and Risks: This research report is for informational purposes only and is not tailored to the specific investment objectives, financial situation or particular requirements of any individual recipient hereof. Certain securities may give rise to substantial risks and may not be suitable for certain investors. Each investor must make its own determination as to the appropriateness of any securities referred to in this research report based upon the legal, tax and accounting considerations applicable to such investor and its own investment objectives or strategy, its financial situation and its investing experience. The value of any security may be positively or adversely affected by changes in foreign exchange or interest rates, as well as by other financial, economic, or political factors. Past performance is not necessarily indicative of future performance or results.



Sources, Completeness and Accuracy: The material herein is based upon information obtained from sources that PCIPL and the research analyst believe to be reliable, but neither PCIPL nor the research analyst represents or guarantees that the information contained herein is accurate or complete and it should not be relied upon as such. Opinions expressed herein are current opinions as of the date appearing on this material, and are subject to change without notice. Furthermore, PCIPL is under no obligation to update or keep the information current. Without limiting any of the foregoing, in no event shall PCIL, any of its affiliates/employees or any third party involved in, or related to computing or compiling the information have any liability for any damages of any kind including but not limited to any direct or consequential loss or damage, however arising, from the use of this document.

Copyright: The copyright in this research report belongs exclusively to PCIPL. All rights are reserved. Any unauthorised use or disclosure is prohibited. No reprinting or reproduction, in whole or in part, is permitted without the PCIPL's prior consent, except that a recipient may reprint it for internal circulation only and only if it is reprinted in its entirety.

Caution: Risk of loss in trading/investment can be substantial and even more than the amount / margin given by you. Investment in securities market are subject to market risks, you are requested to read all the related documents carefully before investing. You should carefully consider whether trading/investment is appropriate for you in light of your experience, objectives, financial resources and other relevant circumstances. PhillipCapital and any of its employees, directors, associates, group entities, or affiliates shall not be liable for losses, if any, incurred by you. You are further cautioned that trading/investments in financial markets are subject to market risks and are advised to seek independent third party trading/investment advice outside PhillipCapital/group/associates/affiliates/directors/employees before and during your trading/investment. There is no guarantee/assurance as to returns or profits or capital protection or appreciation. PhillipCapital and any of its employees, directors, associates, and/or employees, directors, associates of PhillipCapital's group entities or affiliates is not inducing you for trading/investing in the financial market(s). Trading/Investment decision is your sole responsibility. You must also read the Risk Disclosure Document and Do's and Don'ts before investing.

Kindly note that past performance is not necessarily a guide to future performance.

For Detailed Disclaimer: Please visit our website www.phillipcapital.in

For U.S. persons only: This research report is a product of PhillipCapital (India) Pvt Ltd., which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S.-regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances, and trading securities held by a research analyst account.

This report is intended for distribution by PhillipCapital (India) Pvt Ltd. only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by the U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated, and/or transmitted onward to any U.S. person, which is not a Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, PhillipCapital (India) Pvt Ltd. has entered into an agreement with a U.S. registered broker-dealer, Decker & Co, LLC. Transactions in securities discussed in this research report should be effected through Decker & Co, LLC or another U.S. registered broker dealer.

If Distribution is to Australian Investors

This report is produced by PhillipCapital (India) Pvt Ltd and is being distributed in Australia by Phillip Capital Limited (Australian Financial Services Licence No. 246827).

This report contains general securities advice and does not take into account your personal objectives, situation and needs. Please read the Disclosures and Disclaimers set out above. By receiving or reading this report, you agree to be bound by the terms and limitations set out above. Any failure to comply with these terms and limitations may constitute a violation of law. This report has been provided to you for personal use only and shall not be reproduced, distributed or published by you in whole or in part, for any purpose. If you have received this report by mistake, please delete or destroy it, and notify the sender immediately.

PhillipCapital (India) Pvt. Ltd.

Registered office: No. 1, 18th Floor, Urmi Estate, 95 Ganpatrao Kadam Marg, Lower Parel West, Mumbai 400013